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When deliberating on replacement heart valves, two important questionsspring to mind. One is, “How does the replacement valve perform interms of time-related probability of occurrence of failure and other
complications attributable to the device itself?” Answering this question is the basis
for making valid comparisons among different types and models of prosthesis. The
second is, “How likely is it that a patient with a replacement device will survive to
experience a given device-related complication?” Because the make-up (patient mix
or profile) of various groups of patients receiving heart valves differs with respect
to risk factors for mortality, the number of patients living to experience a given
complication will differ and will not be comparable, even though the attributes of
the device remain the same.
Clearly these two questions differ, as do their answers; one addresses intrinsic
properties of the device; the other places these properties into the context of specific
patients or groups of patients. One is apple, the other is orange, and they are not to
be confused.
Actuarial analysis,1 whether by the life table method,2 Kaplan-Meier product
limit calculation,3 or a number of other variants, was originally introduced to
assess survival probability in a population where not everybody is dead at the
time of inquiry.4 The method offered itself as eminently suitable when the
time-related assessment of non-fatal events became a necessity.5 In this case,
however, there is a caveat. Due to its underlying statistical and mathematical
basis, actuarial assessment of a non-fatal event assumes that the entire patient
population will live forever. At first blush, this assumption is preposterous—
nobody lives forever! However, it may not seem so preposterous if stated in
another, completely equivalent way: “We assume that patients who die before a
non-fatal event occurs were just as likely, while they were alive, as anybody else
to have experienced that event, even though they didn’t.” Now, that sounds more
sensible, doesn’t it?
Why should we be interested in this? One of the most useful strategies for
laboratory investigation of a complex phenomenon is to hold all things constant and
vary one thing at a time. Thus, if there are many reactions competing for a single
substrate and we want to understand the characteristics of one of the reactions,
we design the experiment to stop all other reactions except the one of interest.
Patients are mortal, and their life and well-being are threatened continuously by
a broad number of conditions, just as in an uncontrolled laboratory study. A
replacement valve is only one of these conditions thrown into an environment of
multiple competing risks. Despite this, can we isolate the properties of the
device, holding all these competing risks constant, as in a controlled environ-
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exactly the methodology we need, because it isolates one
event at a time from all others, such as the attributes of a
prosthesis.
On the other hand, considering an individual patient, an-
other question arises: “Which is more likely to occur first,
failure of the implanted valve or death?” Indeed, this question
also can be crucial! About 15 years ago, whether or not elective
reoperation was indicated to prevent strut fracture of the Björk-
Shiley valve was just such a question. In 1992, Blackstone and
Kirklin6 worked out the multivariable equations to advise
clinicians on which individual patient should and which should
not be offered elective removal of the valve based on which
competing event, death or strut fracture, was likely to occur
first (this was the first article published in the first issue of The
Journal of Heart Valve Disease).
Two years later, Grunkemeier et al7 asked a simpler
question: “What is the likelihood that a given patient will or
will not suffer a valve-related complication or ultimate
failure of the implanted valve?” They used cumulative
incidence to answer the question, considering the probabil-
ity of death of the patient and that of the valve-related
event as competing risks. Calculation of cumulative in-
cidence is a well-established statistical mathematical
method, and its application in the given context was
perfectly correct.* Other authors went, however, subse-
quently two steps further:
1. They displayed graphically the complement of cumu-
lative incidence, which normally rises from zero to a
certain positive value, so that the new curve declined
from 100% to a certain value.
2. They named this new curve the actual freedom from
a valve-related event; particularly, actual freedom
from structural degeneration of a bioprosthetic valve.
(Note that Grunkemeier et al used the term actual
risk rather than actual freedom.)
Actuarial and actual curves were superimposed on the
same vertical axis, even though one represented a probabil-
ity and the other an upside-down cumulative incidence. The
apples and oranges comparison led to a considerable
amount of confusion. Grunkemeier et al clearly stated that
actual risk is not a statistical term, let alone actual
freedom from an event, and it should be used only (a) to
advise an individual patient or (b) to make some socioeco-
nomic assumptions regarding use of a given device in a
certain patient population. Regrettably, it was not stated
firmly that it must not be used to define and compare
intrinsic valve performances.
*Cumulative incidence dates back to Daniel Bernoulli in the 18th century, who
just a few years before Jenner inoculated 8-year-old James Phipps with cow pox,
contemplated how the population would change if the competing risk of death
from smallpox were eradicated.8 Since then, it has been reinvented multiple
times and given multiple names. Perhaps its first use in heart valve disease was
9by Bodnar and colleagues in 1979, who used the term “multiple decrement”
analysis, as introduced by demographers.
2 The Journal of Thoracic and Cardiovascular Surgery ● JanuarThis led to the Cleveland Clinic reporting actuarial and
actual freedom from valve-related events with the Carpentier-
Edwards Perimount valve in 1998.10 With this, the genie
was out of the bottle.
As per definition, so-called “actual freedom” (which is
not a statistical term, vide supra) is always higher than
actuarial freedom, because the former is influenced by the
non–valve-related mortality of the patient population (that
is, for some patients, death comes before valve explant).
Taking the simplest example, the older the patient, the
larger the difference between “actual” and actuarial free-
dom. As a consequence, so-called “actual” freedom has
been appearing with increasing frequency in publications
reporting valve performance and has been used by some
manufacturers to promote their product. The state of affairs
has become so distorted that there are members (not statis-
ticians) of the medical profession who currently insist that
both actuarial and actual freedoms be given in every pub-
lication reporting long-term performance of replacement
valves. Medical science is suffering a catastrophic blow,
and we must act quickly and decisively to avoid further
damage.
What Should Be Done?
1. We should stop using the term “actual freedom.”
Synonyms of “actual” are current, eventual, and real,
and the implication of its use is that it is more real
than the actuarial estimate. There is no reason to
abandon the expression cumulative incidence if that
is what the authors intend to report, but it must be
used in the proper context.
2. Cumulative incidence (since 1994 called “actual”
freedom in heart valve publications) must not be used
to define or compare valve performance. This should
be done using actuarial methods.
3. All so-called “actual freedom” results published in
the medical literature or in commercial files should
be completely disregarded as invalid descriptions
of valve performance. Only actuarial results should
be used to describe device performance. Any state-
ment of device performance based on “actual free-
dom” from valve-related events should be consid-
ered scientifically invalid and potentially mis-
leading.
In conclusion, the Journal will no longer publish “actual
freedom” results in articles reporting long-term perfor-
mance of replacement valves. We will ask our authors to
provide cumulative incidence if relevant, but not as a mea-
sure of durability or quality of a replacement device, for
which actuarial results are required. This approach must
become consistent in scientific publications and in advertis-
ing material.8,9
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